Abstract
Satinder Kaur
Purpose The aim of this article was to study survival outcomes of early-stage cervical cancer
patients and impact on survival after restaging them as per International Federation
of Gynecology and Obstetrics (FIGO) 2018.
Materials and Methods A retrospective study was conducted from June 1, 2013 to May 31, 2018 in a tertiary
care hospital in North India. One-hundred patients of early-stage cervical cancer
(as per FIGO 2009 staging) who had been treated by surgery followed by risk based
tailored adjuvant therapy in our hospital were evaluated. The clinicopathological
features and survival outcomes of these patients were analyzed. These patients were
then restaged as per new FIGO 2018 staging and survival outcomes between two FIGO
classifications were compared.
Results The median age of the study population was 52.5 years with median follow-up of 62.1
months. Ninety percent of our patients had more than 2 years follow-up and 59% had
more than 5 years follow-up. The overall survival and relapse-free survival were 87.5
and 91.4%, respectively. The study population was then reclassified according to new
FIGO 2018 staging. It was seen that the patients with stage IB1and IB2 cervical cancer
had overall survival of 91.1 and 90%, respectively. The overall survival of stage
IB3 was 80% and the survival of stage IIIC1 was only 60%.
Conclusion The new FIGO 2018 classification has a significant effect on survival outcome and
in prognostication of patients with cervical cancer.
Keywords
early stage cervical cancer - FIGO staging
